U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06810947) titled 'Evaluation of Treatments for Allergic Rhinitis (Rhinal 2)' on Jan. 31.
Brief Summary: The goal of this clinical study is to perform a post-market clinical follow-up of 2 medical devices (liquid bandage in the form of a spray : ALLERSPRAY G (product A - code AAG), PCNS (product B - code PC) indicated for symptomatic treatment of allergic rhinitis. This follow-up will consist in collecting real-life clinical data to confirm the safety and efficacy of medical devices used in the treatment of allergic rhinitis of adults patients while allowing an assessment of the product's risk/benefit ratio.
The main questions it aims to answer are:
...